Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Assessment of Added Activity of An Antitumor Agent

Cong Chen, Linda Zhiping Sun, Yixin Ren, Eric H. Rubin, David M. Weinstock, Emmett V. Schmidt
doi: https://doi.org/10.1101/2022.10.14.22281099
Cong Chen
1Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ 07065, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cong_chen@merck.com
Linda Zhiping Sun
1Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ 07065, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yixin Ren
1Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ 07065, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric H. Rubin
2Oncology Early Development, Merck & Co., Inc., Rahway, NJ 07065, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David M. Weinstock
3Discovery Oncology, Merck & Co., Inc., Rahway, NJ 07065, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emmett V. Schmidt
2Oncology Early Development, Merck & Co., Inc., Rahway, NJ 07065, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

An unprecedented number of novel oncology drugs are under preclinical and clinical development, and nearly all are developed in combinations. With an over-reliance on biological hypotheses, there is less effort to establish single agent activity before initiating late clinical development. This may be contributing to a decreased success rate going from phase 1 to approval in the immunotherapy era. Growing evidence in clinical trial data shows that the treatment benefit from most approved combination therapies can be explained by the independent drug action model. Using this working model, we develop a simple index to measure the added antitumor activity of a new drug based on mean response duration, an endpoint that naturally combines both response status and duration information for all patients, which is shown to be highly predictive of clinical benefit of FDA-approved anti-PD-(L)1 immunotherapies. This index sheds light on challenges and opportunities in contemporary oncology drug development and provides a practical tool to assist with decision-making.

Competing Interest Statement

All authors are stockholders of pharmaceutical companies and can potentially benefit from the publication of this research work.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted October 17, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Assessment of Added Activity of An Antitumor Agent
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Assessment of Added Activity of An Antitumor Agent
Cong Chen, Linda Zhiping Sun, Yixin Ren, Eric H. Rubin, David M. Weinstock, Emmett V. Schmidt
medRxiv 2022.10.14.22281099; doi: https://doi.org/10.1101/2022.10.14.22281099
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Assessment of Added Activity of An Antitumor Agent
Cong Chen, Linda Zhiping Sun, Yixin Ren, Eric H. Rubin, David M. Weinstock, Emmett V. Schmidt
medRxiv 2022.10.14.22281099; doi: https://doi.org/10.1101/2022.10.14.22281099

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (506)
  • Anesthesia (110)
  • Cardiovascular Medicine (1245)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (534)
  • Epidemiology (10032)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2467)
  • Geriatric Medicine (238)
  • Health Economics (480)
  • Health Informatics (1647)
  • Health Policy (754)
  • Health Systems and Quality Improvement (637)
  • Hematology (250)
  • HIV/AIDS (536)
  • Infectious Diseases (except HIV/AIDS) (11872)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (253)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2290)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1249)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (325)
  • Pediatrics (734)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2281)
  • Public and Global Health (4844)
  • Radiology and Imaging (843)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (652)
  • Rheumatology (286)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (227)
  • Surgery (269)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)